TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21511841

Group type: EXPERIMENTAL
Intervention: Modeled volume (V(m))
Number of subjects: 1846

Group type: EXPERIMENTAL
Intervention: Higher modeled volume (V(m)) after adjustment for V(ant)
Number of subjects: 1846

Group type: COMPARATOR
Intervention: V(ant) (calculated from anthropometric measurements)
Number of subjects: 1846
Study: 19070418

Group type: EXPERIMENTAL
Intervention: Tolterodine ER 4 mg per day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo plus alpha‐blocker
Number of subjects: 0
Study: 16796706

Group type: EXPERIMENTAL
Intervention: Itraconazole administered orally for 6 days, with fexofenadine on days 1, 3, and 6.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fexofenadine administered alone.
Number of subjects: 0
Study: 14501605

Group type: EXPERIMENTAL
Intervention: Ospemifene 30 mg
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Ospemifene 60 mg
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Ospemifene 90 mg
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Ospemifene (all doses)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study: 10966065

Group type: EXPERIMENTAL
Intervention: Bifocal lenses with a +1.50 D add (n = 42)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Single-vision glasses (n = 40)
Number of subjects: 82
Study: 8761577

Group type: EXPERIMENTAL
Intervention: Albendazole
Number of subjects: 246

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 246
Study: 1551743

Group type: EXPERIMENTAL
Intervention: 15(s) 15 Me PGF2 alpha intravesical instillation (1 mg daily for a maximum of 5 days)
Number of subjects: 19

Group type: COMPARATOR
Intervention: 1% alum irrigation of bladder (5 ml/min for a maximum period of 72 hours)
Number of subjects: 19
Study: 3553479

Group type: EXPERIMENTAL
Intervention: K‐rich/Na‐poor salt (2 g twice daily for 8 days)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Common salt (CS) (2 g twice daily for 8 days)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: K‐rich/Na‐poor salt
Number of subjects: 10

Group type: COMPARATOR
Intervention: Common salt (CS)
Number of subjects: 10
Study: 31394308

Group type: EXPERIMENTAL
Intervention: Anodal high-definition transcranial direct current stimulation (tDCS) over the right dorsolateral prefrontal cortex (dlPFC)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham stimulation (control)
Number of subjects: 20
Study: 31287523

Group type: EXPERIMENTAL
Intervention: Recombinant zoster vaccine (n=922)
Number of subjects: 1846

Group type: COMPARATOR
Intervention: Placebo (n=924)
Number of subjects: 1846

Group type: EXPERIMENTAL
Intervention: Recombinant zoster vaccine
Number of subjects: 1846

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1846
Study: 28320895

Group type: EXPERIMENTAL
Intervention: Peripheral venous congestion at 15 mmHg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Peripheral venous congestion at 30 mmHg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Decongestion after 60 min
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (noncongested arm)
Number of subjects: 20
Study: 26154928

Group type: EXPERIMENTAL
Intervention: Accelerated RRT initiation (12 hours or less from eligibility)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Standard RRT initiation (more than 12 hours from eligibility)
Number of subjects: 101
Study: 24299565

Group type: EXPERIMENTAL
Intervention: DPT (Dpt extract)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: DPT+MRB (Dpt plus mixed respiratory bacterial extracts)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 102
Study: 21143591

Group type: EXPERIMENTAL
Intervention: Water-based lubricants
Number of subjects: 2453

Group type: EXPERIMENTAL
Intervention: Silicone-based lubricants
Number of subjects: 2453
Study: 18999335

Group type: EXPERIMENTAL
Intervention: Family Check-Up (FCU)
Number of subjects: 731

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 731
Study: 16870552

Group type: EXPERIMENTAL
Intervention: Arsenic trioxide (AT) at a dose of 0.25 mg/kg/day intravenously for 5-7 days per week for up to 60 days.
Number of subjects: 11
Study: 14648922

Group type: EXPERIMENTAL
Intervention: Pro-hemostatic therapy
Number of subjects: 0
Study: 11775643

Group type: EXPERIMENTAL
Intervention: Essaven gel (EG)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 9272232

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment (twice a week for 5 weeks)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (untreated subfertile males)
Number of subjects: 32
Study: 8496303

Group type: EXPERIMENTAL
Intervention: Continuous infusion of recombinant human GH (group 1)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Daily injection of recombinant human GH (group 2)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Switch from continuous infusion to daily injections (group 1 during second period)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Daily injection of recombinant human GH (group 2 during second period)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Group 1
Number of subjects: 18
Study: 3688597

Group type: EXPERIMENTAL
Intervention: Alcohol and Substance Abuse Prevention Program (ASAP)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 27
Study: 30747899

Group type: EXPERIMENTAL
Intervention: Triple hop (TH) test
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Single hop (SH) test
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Crossover hop (XH) test
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Isometric hip strength tests
Number of subjects: 68
Study: 30339489

Group type: EXPERIMENTAL
Intervention: Er:YAG laser (1.5-W power, 150-mJ pulse energy, 10-Hz frequency, 500-μs pulse duration, 0.9-mm spot size)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Traditional scalpel surgery
Number of subjects: 117
Study: 27151177

Group type: EXPERIMENTAL
Intervention: Sitagliptin 100mg/day
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 25190434

Group type: EXPERIMENTAL
Intervention: peg‐IFN alfa‐2a (180 µg/week) for 48 weeks (monotherapy)
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: peg‐IFN alfa‐2a (180 µg/week) for 48 weeks with ETV add-on (0.5 mg/daily starting at week 13)
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: peg‐IFN alfa‐2a (180 µg/week) for 48 weeks with ETV pretreatment (0.5 mg/daily for 24 weeks starting before peg‐IFN)
Number of subjects: 218
Study: 24125796

Group type: EXPERIMENTAL
Intervention: CRT-D
Number of subjects: 419

Group type: COMPARATOR
Intervention: CRT pacemaker
Number of subjects: 419
Study: 22192866

Group type: EXPERIMENTAL
Intervention: LABA or LAMA
Number of subjects: 523

Group type: EXPERIMENTAL
Intervention: LABA and LAMA
Number of subjects: 523

Group type: EXPERIMENTAL
Intervention: LABA, LAMA and ICS
Number of subjects: 523
Study: 18367398

Group type: EXPERIMENTAL
Intervention: Bio‐interference Screws fixation (Group 1)
Number of subjects: 30

Group type: COMPARATOR
Intervention: BioTransFix femur extra cortical transverse fixation (Group 2)
Number of subjects: 30
Study: 16848911

Group type: EXPERIMENTAL
Intervention: Early protocol with atropine at 10 and 20 mcg/kg/min of dobutamine (Groups A&B)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Standard protocol with atropine at 40 mcg/kg/min of dobutamine (Group C)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Early administration of atropine (Groups A&B)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Atropine administration
Number of subjects: 121
Study: 12776843

Group type: EXPERIMENTAL
Intervention: Carbohydrate-restricted diet
Number of subjects: 17

Group type: COMPARATOR
Intervention: Noncarbohydrate-restricted diet
Number of subjects: 17
Study: 10831025

Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 9248871

Group type: EXPERIMENTAL
Intervention: mianserin (10-60 mg/day)
Number of subjects: 66

Group type: COMPARATOR
Intervention: haloperidol (2-6 mg/day)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: mianserin and haloperidol
Number of subjects: 66
Study: 8448266

Group type: EXPERIMENTAL
Intervention: Biperiden (6 mg)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 2881975

Group type: EXPERIMENTAL
Intervention: Drug treatment for general anxiety
Number of subjects: 61

Group type: COMPARATOR
Intervention: Nonalcoholic placebo
Number of subjects: 61

Group type: COMPARATOR
Intervention: Alcohol placebo
Number of subjects: 61
Study: 30282858

Group type: EXPERIMENTAL
Intervention: Daiokanzoto sherbets
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Hangeshashinto sherbets
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 23
Study: 24714209

Group type: EXPERIMENTAL
Intervention: Mindfulness-based mind fitness training (MMFT), 20 hours
Number of subjects: 0

Group type: COMPARATOR
Intervention: Training as usual (control)
Number of subjects: 0
Study: 23989106

Group type: EXPERIMENTAL
Intervention: 3-day amoxicillin (80 mg/kg/d; divided into 3 daily doses)
Number of subjects: 125

Group type: COMPARATOR
Intervention: 10-day amoxicillin (80 mg/kg/d; divided into 3 daily doses)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: 5-day amoxicillin (80 mg/kg/d; divided into 3 daily doses)
Number of subjects: 125
Study: 22805400

Group type: EXPERIMENTAL
Intervention: 5 IU PPD tuberculin test
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: 10 IU PPD tuberculin test
Number of subjects: 255
Study: 21243928

Group type: EXPERIMENTAL
Intervention: Grass allergy immunotherapy tablet (Grazax), treatment lasted at least 8 weeks before the grass pollen season and continued until the season finished
Number of subjects: 78

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study: 19115441

Group type: EXPERIMENTAL
Intervention: Cognitive‐Behavioural Therapy (CBT) in addition to treatment as usual
Number of subjects: 90

Group type: COMPARATOR
Intervention: Treatment as usual only
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Cognitive‐Behavioural Therapy (CBT)
Number of subjects: 90
Study: 20540254

Group type: EXPERIMENTAL
Intervention: Arteriovenous impulse system (AVIS) combined with low-molecular-weight heparins calcium (LMWHC)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Low-molecular-weight heparins calcium (LMWHC) alone
Number of subjects: 76
Study: 15574663

Group type: EXPERIMENTAL
Intervention: Facial expressions of anger
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Facial expressions of fear
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Characteristics associated with babyishness
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Characteristics associated with maturity
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Composite faces used in Study 3
Number of subjects: 0
Study: 12141374

Group type: EXPERIMENTAL
Intervention: Dental technicians
Number of subjects: 52

Group type: COMPARATOR
Intervention: Porcelain process
Number of subjects: 52

Group type: COMPARATOR
Intervention: Polishing process
Number of subjects: 52
Study: 9521514

Group type: EXPERIMENTAL
Intervention: Suction drainage
Number of subjects: 98

Group type: COMPARATOR
Intervention: No drainage
Number of subjects: 98
Study: 7805080

Group type: EXPERIMENTAL
Intervention: Anticoagulant therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antithrombotic therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antithrombotic treatment
Number of subjects: 0
Study: 2688659

Group type: EXPERIMENTAL
Intervention: Information provided by phone
Number of subjects: 439

Group type: EXPERIMENTAL
Intervention: Information provided in person at the clinic
Number of subjects: 439

Group type: COMPARATOR
Intervention: Control group (not contacted by phone or clinic)
Number of subjects: 439
Study: 1102398

Group type: EXPERIMENTAL
Intervention: Fresh frozen plasma therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no fresh frozen plasma therapy)
Number of subjects: 0
Study: 11722966

Group type: EXPERIMENTAL
Intervention: Bifidobacterium lactis HN019 (5 x 10(10) organisms/d or 5 x 10(9) organisms/d)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Bifidobacterium lactis HN019
Number of subjects: 30

Group type: COMPARATOR
Intervention: Low-fat milk (200 mL twice daily for 3 wk)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Low-fat milk (during stage 3)
Number of subjects: 30
Study: 31454802

Group type: EXPERIMENTAL
Intervention: 4 g omega-3 fatty acids (1,840 mg eicosapentaenoic acid and 1,520 mg docosahexaenoic acid) a day for 4 weeks
Number of subjects: 20
Study: 30138162

Group type: EXPERIMENTAL
Intervention: Laparoscopic approach
Number of subjects: 66

Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 66
Study: 27168479

Group type: EXPERIMENTAL
Intervention: Classroom-based activity break led by teachers (5-min activity break three times per day for 12 weeks)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (no activity break)
Number of subjects: 120
Study: 24442928

Group type: EXPERIMENTAL
Intervention: Peg‐IFN alpha‐2b monotherapy for 24 weeks (1.5 μg/kg/week)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Peg‐IFN alpha‐2b monotherapy for 12 weeks (1.5 μg/kg/week)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Peg‐IFN alpha‐2b in combination with RBV for 12 weeks (10.6 mg/kg/day)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Overall SVR rate
Number of subjects: 130
Study: 22291438

Group type: EXPERIMENTAL
Intervention: Vernakalant (3.0 mg/kg infusion for 10 min)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Vernakalant (2.0 mg/kg infusion if AFL or AF persisted)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Vernakalant
Number of subjects: 54
Study: 20297861

Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 5096

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5096
Study: 17937943

Group type: EXPERIMENTAL
Intervention: Buccal mucosa dorsal onlay urethroplasty
Number of subjects: 55

Group type: COMPARATOR
Intervention: Penile skin flap dorsal onlay urethroplasty
Number of subjects: 55
Study: 16555564

Group type: EXPERIMENTAL
Intervention: 100 mL of contrast material with 30 mL of saline flush (group B)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: 85 mL of contrast material with 30 mL of saline flush (group C)
Number of subjects: 88

Group type: COMPARATOR
Intervention: 100 mL of contrast material alone (group A)
Number of subjects: 88
Study: 12473052

Group type: EXPERIMENTAL
Intervention: ENP-led care (n = 99)
Number of subjects: 199

Group type: COMPARATOR
Intervention: SHO-led care (n = 100)
Number of subjects: 199
Study: 10728182

Group type: EXPERIMENTAL
Intervention: Acupuncture (12 weekly sessions of minimal acupuncture and somatic moxibustion-acupuncture associated with auriculopuncture)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (12 weekly sessions)
Number of subjects: 40
Study: 7852511

Group type: EXPERIMENTAL
Intervention: 10 mg cisapride
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Ang II perfusion (1-4 ng/kg.min)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 10 mg cisapride + Ang II perfusion
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo perfusion
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Low sodium diet (10 mmol/day)
Number of subjects: 8
Study: 1952202

Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 0
Study: 6946205

Group type: EXPERIMENTAL
Intervention: Chlorhexidine digluconate mouthrinses
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 31592915

Group type: EXPERIMENTAL
Intervention: Combination therapy with topical poly-lactic acid and microneedle fractional radiofrequency (MFRF)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Microneedle fractional radiofrequency (MFRF) with normal saline (Control)
Number of subjects: 0
Study: 30569273

Group type: EXPERIMENTAL
Intervention: Teplizumab (anti-CD3 monoclonal antibody)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group (original participants who did not receive teplizumab)
Number of subjects: 56
Study: 28538639

Group type: EXPERIMENTAL
Intervention: Emergency Preservation and Resuscitation (EPR) initiated via an intra‐aortic flush of a large volume of ice‐cold saline solution.
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no EPR intervention).
Number of subjects: 20
Study: 24728533

Group type: EXPERIMENTAL
Intervention: Phacoemulsification with posterior chamber intraocular lens (IOL) implantation
Number of subjects: 30

Group type: COMPARATOR
Intervention: Laser peripheral iridotomy (LPI)
Number of subjects: 30
Study: 24345974

Group type: EXPERIMENTAL
Intervention: Strength training regimen from baseline to 16 weeks
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Detraining period from 16 to 32 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no strength training)
Number of subjects: 20
Study: 21685813

Group type: EXPERIMENTAL
Intervention: LEUPRO (leucine/protein/CHO/fat supplement 7.5/20/89/22 g · h(‐1))
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (isocaloric CHO/fat 119/22 g · h(‐1))
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: LEUPRO
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control
Number of subjects: 12
Study: 19261927

Group type: EXPERIMENTAL
Intervention: RECIST
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Choi criteria
Number of subjects: 37
Study: 17477865

Group type: EXPERIMENTAL
Intervention: AS/AQ
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: AS/SP
Number of subjects: 220

Group type: COMPARATOR
Intervention: Molecular genotyping study
Number of subjects: 220
Study: 15180735

Group type: EXPERIMENTAL
Intervention: Azathioprine (AZA) alone (2.2 mg/kg)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Azathioprine (AZA) with olsalazine (0.5 g tid)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Combination therapy (AZA + olsalazine)
Number of subjects: 70
Study: 11772451

Group type: EXPERIMENTAL
Intervention: Intravesical mitomycin C therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pretreatment that induces apoptosis and reduces cell density
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Treatment schedules designed to take advantage of drug-induced changes in tumor tissue composition
Number of subjects: 0
Study: 9819288

Group type: EXPERIMENTAL
Intervention: salbutamol (8 mg BD)
Number of subjects: 25

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 25
Study: 7641724

Group type: EXPERIMENTAL
Intervention: Fentanyl (2.5 micrograms kg‐1)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Ketamine (1 mg kg‐1)
Number of subjects: 60
Study: 2768665

Group type: EXPERIMENTAL
Intervention: Interaction with ADD/CD child confederates
Number of subjects: 0

Group type: COMPARATOR
Intervention: Interaction with normal child confederates
Number of subjects: 0
Study: 921868

Group type: EXPERIMENTAL
Intervention: Enflurane
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Halothane
Number of subjects: 99
Study: 31119807

Group type: EXPERIMENTAL
Intervention: Visual assessment by dermatologists
Number of subjects: 392

Group type: COMPARATOR
Intervention: Automated diagnosis algorithm
Number of subjects: 392
Study: 28332984

Group type: EXPERIMENTAL
Intervention: Intensity Modulated Radiation Therapy (IMRT) with a simultaneous integrated boost (SIB) of 82 Gy to regions of increased uptake on ProstaScint scans, total dose of 75.6 Gy in 42 fractions, with adjuvant hormonal therapy for intermediate- and high-risk patients.
Number of subjects: 71

Group type: COMPARATOR
Intervention: Intensity Modulated Radiation Therapy (IMRT) without the simultaneous integrated boost (SIB).
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Intensity Modulated Radiation Therapy (IMRT) with SIB.
Number of subjects: 71
Study: 25860913

Group type: EXPERIMENTAL
Intervention: 10 phone counselling sessions and 21 short message service messages for abstinence and coronary disease prevention (Experimental group, n=30)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Standard education (Control group, n=32)
Number of subjects: 62
Study: 23335698

Group type: EXPERIMENTAL
Intervention: Upper limb training (UL)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Lower limb training (LL)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Comparison of UL and LL groups
Number of subjects: 43
Study: 19615769

Group type: EXPERIMENTAL
Intervention: LA volume measurements (LAV(max), LAV(min)) using multi-detector computed tomography (CT)
Number of subjects: 377

Group type: EXPERIMENTAL
Intervention: Top quartile LAV(max) and LAV(min)
Number of subjects: 377

Group type: EXPERIMENTAL
Intervention: LA volumes added to CT finding of indeterminate stenosis
Number of subjects: 377
Study: 19567208

Group type: EXPERIMENTAL
Intervention: Docetaxel in combination with doxorubicin and cyclophosphamide (TAC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Docetaxel in an unlicensed sequential regimen FEC100-T
Number of subjects: 0

Group type: COMPARATOR
Intervention: TAC compared with FAC
Number of subjects: 0

Group type: COMPARATOR
Intervention: FEC100-T compared with FEC100
Number of subjects: 0
Study: 17178978

Group type: EXPERIMENTAL
Intervention: Losartan-based treatment
Number of subjects: 881

Group type: COMPARATOR
Intervention: Atenolol-based treatment
Number of subjects: 881
Study: 15369455

Group type: EXPERIMENTAL
Intervention: Parathyroid carcinoma (PC)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Aneuploid parathyroid carcinoma (PC)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Diploid parathyroid carcinoma (PC)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Parathyroid adenoma (PA)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Overall postoperative survival in patients with PC
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Correlation between DI and AgNOR counts
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Correlation between survival and DI
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Correlation between survival and AgNOR counts
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Correlation between preoperative biochemical parameters and survival
Number of subjects: 15